Expand ENTX Menu
ENTX MENU

ENTX Latest Press Releases

-- August 27, 2026 --

Correction: Entera to Participate in Upcoming Fall Investor Conferences Globe Newswire 9:44 AM
Entera to Participate in Upcoming Fall Investor Conferences Globe Newswire 8:00 AM

-- August 18, 2026 --

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation Globe Newswire 8:00 AM

-- August 7, 2026 --

Entera Announces Second Quarter 2026 Financial Results and Business Updates Globe Newswire 4:05 PM

-- August 4, 2026 --

Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting Globe Newswire 8:30 AM

-- July 31, 2026 --

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference Globe Newswire 4:30 PM

-- July 29, 2026 --

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE PRNewswire 3:00 PM

-- July 27, 2026 --

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement Globe Newswire 8:30 AM

-- June 23, 2026 --

Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market Globe Newswire 8:50 AM

-- June 22, 2026 --

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Globe Newswire 8:30 AM

-- June 16, 2026 --

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 Globe Newswire 8:33 AM

-- June 15, 2026 --

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) Globe Newswire 8:45 AM

-- May 28, 2026 --

Entera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation Globe Newswire 8:50 AM

-- May 8, 2026 --

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs Globe Newswire 4:05 PM

-- April 20, 2026 --

BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity Globe Newswire 11:59 AM

-- April 14, 2026 --

Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 Globe Newswire 8:45 AM

-- April 6, 2026 --

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners PRNewswire 1:50 PM
Market Data Delayed 15 Minutes